Drug Profile
A 316023
Latest Information Update: 24 Jun 2002
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Gelatinase inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Sep 2000 New profile
- 11 Sep 2000 Preclinical development for Cancer in USA (Unknown route)